Goodall et al. studied ctDNA WES in TOPARP-A, where ctDNA was identified in 93% of patients and captured all BRCA1, BRCA2, and ATM alterations identified in tumor biopsies, along with newly identified mutations associated with disease progression [74]. The gene discussed is BRCA2; the disease is neoplasm.